HIV co-infection and HCV-induced liver fibrosis in vivo

HIV合并感染和HCV诱导的体内肝纤维化

基本信息

  • 批准号:
    8383475
  • 负责人:
  • 金额:
    $ 34.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-12-01 至 2016-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection and HIV coinfection act synergistically to promote hepatic fibrosis and cirrhosis, but the underlying pathogenic mechanisms remain unclear due to a lack of appropriate animal models. The BalbC rag2/?C double knockout (DKO) mouse lacks T, B and NK cells and supports development of a functional human immune system in all lymphoid organs. To promote human liver cell co-engraftment, we introduced a liver-specific inducible suicidal transgene (AFC8) in the DKO mouse. Co-transplantation of human blood and liver progenitor cells in AFC8 mice leads to development of both human liver cells and immune cells in lymphoid/liver organs (AFC8-hu mice). These mice are permissive for HCV as well as HIV infection, support anti-viral human T cell responses, and develop human liver immunopathology (inflammation, hepatitis and fibrosis). I postulate that HIV co-infection may affect HCV-induced liver diseases by enhancing HCV replication; by elevating chronic hepatic inflammation; and by activating hepatic stellate cells to accelerate liver fibrosis. The AFC8-hu model is well suited for elucidating the mechanism underlying HCV/HIV synergy in human hepatic fibrosis in vivo. We propose the following aims: 1) The current AFC8-hu mouse will be improved to support higher human hepatocytes in the chimeric liver. In addition, HCV gt 1a and 2a clones will be tested to establish their infection and pathogenesis kinetics. 2) To study how HIV co-infection exacerbates HCV-induced liver fibrosis in AFC8-hu mice. We will define how HIV infection influences HCV infection, immunopathogenesis, stellate cell activation and liver fibrosis. In addition, the effectof HCV infection on HIV-1 replication and AIDS progression will also be monitored. 3) I propose that HIV coinfection dysregulates human inflammatory and immune responses to contribute to HCV-associated liver diseases. We will define the role of key HIV target cells pDC and Treg that promote HCV-induced liver stellate cell activation and fibrosis in vitro and in vivo. The novel AFC8-hu mouse is unique in providing a small animal model in which these important questions can be addressed. The answers to these questions will have a very significant impact on the field.
描述(由申请人提供):丙型肝炎病毒(HCV)感染和HIV合并感染协同作用,促进肝纤维化和肝硬化,但由于缺乏适当的动物模型,潜在的致病机制仍不清楚。BalbC Rag2/?C双敲除(DKO)小鼠缺乏T、B和NK细胞,并支持所有淋巴器官中功能性人免疫系统的发育。为了促进人肝细胞共移植,我们在DKO小鼠中引入了肝脏特异性诱导自杀转基因(AFC 8)。在AFC 8小鼠中共移植人血和肝祖细胞导致淋巴/肝器官(AFC 8-hu小鼠)中人肝细胞和免疫细胞的发育。这些小鼠允许HCV和HIV感染,支持抗病毒人类T细胞应答,并发展人类肝脏免疫病理学(炎症,肝炎和纤维化)。我推测,HIV合并感染可能会影响HCV诱导的肝脏疾病,通过增强HCV复制,通过升高慢性肝脏炎症,并通过激活肝星状细胞加速肝纤维化。AFC 8-hu模型非常适合于阐明体内HCV/HIV协同作用在人肝纤维化中的机制。我们提出了以下目标:1)目前的AFC 8-hu小鼠将被改进以支持嵌合肝脏中的更高的人肝细胞。此外,还将检测HCV gt 1a和2a克隆, 它们的感染和致病动力学。2)研究HIV合并感染如何加重HCV诱导的AFC 8-hu小鼠肝纤维化。我们将明确HIV感染如何影响HCV感染、免疫发病机制、星状细胞活化和肝纤维化。此外,还将监测HCV感染对HIV-1复制和AIDS进展的影响。3)我认为HIV合并感染导致人类炎症和免疫反应失调,从而导致HCV相关的肝脏疾病。我们将确定关键的HIV靶细胞pDC和Treg在体外和体内促进HCV诱导的肝星状细胞活化和纤维化的作用。新型AFC 8-hu小鼠在提供可以解决这些重要问题的小动物模型方面是独一无二的。这些问题的答案将对该领域产生非常重大的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lishan Su其他文献

Lishan Su的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lishan Su', 18)}}的其他基金

Immune Mechanisms of Elevated Liver Diseases During HIV Infection
HIV 感染期间肝病升高的免疫机制
  • 批准号:
    10461881
  • 财政年份:
    2021
  • 资助金额:
    $ 34.78万
  • 项目类别:
Immune Mechanisms of Elevated Liver Diseases During HIV Infection
HIV 感染期间肝病升高的免疫机制
  • 批准号:
    10240509
  • 财政年份:
    2021
  • 资助金额:
    $ 34.78万
  • 项目类别:
Immune Mechanisms of Elevated Liver Diseases During HIV Infection
HIV 感染期间肝病升高的免疫机制
  • 批准号:
    10359221
  • 财政年份:
    2021
  • 资助金额:
    $ 34.78万
  • 项目类别:
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
保留 CTLA-4 免疫检查点以实现更安全、更有效的癌症免疫治疗
  • 批准号:
    10669173
  • 财政年份:
    2020
  • 资助金额:
    $ 34.78万
  • 项目类别:
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
保留 CTLA-4 免疫检查点以实现更安全、更有效的癌症免疫治疗
  • 批准号:
    10457311
  • 财政年份:
    2020
  • 资助金额:
    $ 34.78万
  • 项目类别:
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence
HIV-1 Vpr 破坏 IFN-TET-ISG 通路,促进 HIV-1 感染和持续存在
  • 批准号:
    10371668
  • 财政年份:
    2016
  • 资助金额:
    $ 34.78万
  • 项目类别:
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence
HIV-1 Vpr 破坏 IFN-TET-ISG 通路,促进 HIV-1 感染和持续存在
  • 批准号:
    10015198
  • 财政年份:
    2016
  • 资助金额:
    $ 34.78万
  • 项目类别:
HIV co-infection and HCV-induced liver fibrosis in vivo
HIV合并感染和HCV诱导的体内肝纤维化
  • 批准号:
    8584278
  • 财政年份:
    2011
  • 资助金额:
    $ 34.78万
  • 项目类别:
HIV co-infection and HCV-induced liver fibrosis in vivo
HIV合并感染和HCV诱导的体内肝纤维化
  • 批准号:
    8263237
  • 财政年份:
    2011
  • 资助金额:
    $ 34.78万
  • 项目类别:
HIV-1 Replication and Pathogenesis in vivo
HIV-1体内复制和发病机制
  • 批准号:
    8288315
  • 财政年份:
    2009
  • 资助金额:
    $ 34.78万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了